N/A N=20 Retrospective Analysis of the Experience With Larotrectinib in Patients With Solid Neoplasms With NTRK Fusion in Spain (SPAINTRK)
Solid Neoplasms With NTRK Fusions
Primary: Duration of Response (DoR) — 24.5 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=67 Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia
Menorrhagia
Primary: Menstrual Blood Loss (MBL) as Measured by Pictorial Blood Loss Assessment Chart (PBLAC). — 15; 0 units on a scale — p=0.003
Phase 2 N=73 Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer
Endometrial Carcinoma · Recurrent Uterine Corpus Carcinoma · Stage IIIA Uterine Corpus Cancer
Primary: Percentage of Participants With a Confirmed Objective Tumor Response Using RECIST Version 1.0 — 22; 14.3 percentage of participants
Phase 2 N=150 Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma
Endometrial Atypical Hyperplasia · Endometrial Adenocarcinoma
Primary: Cumulative CR Rates Within 16 Weeks — 23; 12 Participants
Phase 2 N=30 Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms
Blasts 10 Percent or More of Bone Marrow Nucleated Cells · Chronic Myelomonocytic Leukemia-2 · High Grade Malignant Neoplasm
Primary: Feasibility of Early Allogeneic Hematopoietic Cell Transplant Assessed by Enrollment and Incidence of Early Transplant — 9; 21 Participants
Phase 2 N=77 Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
Peripheral T Cell Lymphoma · PTCL · Extranodal NK/T-cell Lymphoma
Primary: Overall Response Rate (ORR) — 31.8; 20.5; 45.5 Percentage of participants
Phase 1 N=10 MK-3475 Immunotherapy in Endometrial Carcinoma
Endometrial Cancer · Endometrial Carcinoma · Neoplasms, Endometrial
Primary: Safety as Measured by Any Grade Treatment Related Adverse Events Experienced by ≥ 2 Patients — 10; 9; 8; 8 Participants
Phase 2 N=30 ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma
Triple Negative Breast Cancer · Endometrial Cancer · Hormone Receptor Positive, HER2 Negative Breast Cancer
Primary: Cohort 1 - Progression-free Survival (PFS) — 1.9 Months
Phase 2 N=40 Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer
Atypical Hyperplasia · Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia · Endometrial Carcinoma
Primary: Change in Tumor Proliferation — -0.17 percent (represented by mean) of cells
N/A N=100 Adipocytokines in Endometrial Cancer
Endometrial Cancer · Obesity
Primary: Correlation Between Circulating Levels of These Markers and Demographic Characteristics. — 39; 42; 11; 8 Participants — p=0.026
Phase 2 N=50 Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer
Recurrent Endometrial Endometrioid Adenocarcinoma · Recurrent Uterine Corpus Carcinoma · Stage III Uterine Corpus Cancer AJCC v7
Primary: Clinical Activity of Combination Enzalutamide, Carboplatin and Paclitaxel Represented as Objective Tumor Response (Complete Response (CR) + Partial Response (PR)). — 68…
N/A N=10 Pilot Study: Can Ultrasound Guided Biopsy be Used as an Alternative to Hysteroscopy?
Endometrial Cancer · Endometrial Neoplasms · Endometrial Hyperplasia
Primary: Number of Participants Whose Sample Was Successfully Analysed by Histological Diagnosis — 9 Participants
Phase 4 N=24 Clinical Trial Comparing Endometrial Transformation With Subcutaneous Progesterone Versus Intramuscular Progesterone
Reproductive Techniques, Assisted
Primary: Predecidual Transformation — 1; 2; 7; 8 participants — p=0.3395
Phase 2 N=49 VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
Recurrent Endometrial Carcinoma
Primary: 6 Month Progression-free Survival — 18 participants
Phase 2 N=30 Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate
Atypical Endometrial Hyperplasia · Endometrial Carcinoma
Primary: Best Pathologic Responses — 17; 4; 6; 1 participants